R&D channel feed – Endpoints News

R&D channel feed

Versartis shares hammered by a PhIII flop as growth hormone flunks key test

8 years ago

Nestle plans to ax hundreds of R&D staffers, shutter big dermatology campus

8 years ago

Want to start fixing the gender diversity problem in your biotech company? Put down the silver bullet

8 years ago

Alnylam achieves breakthrough RNAi success as PhIII patisiran study hits all goals, shares soar

8 years ago

AbbVie and Roche tout a positive PhIII combo study of Venclexta, Rituxan in CLL — ahead of FDA pitch

8 years ago

Shares rocket up as Nabriva Therapeutics touts a PhIII win for antibiotic

8 years ago

Closing in on another mega-raise, UK biotech star Immunocore grabs $40M investment from Gates Foundation

8 years ago

Kerrisdale 2-0 this week: Bavarian Nordic's cancer vaccine is a bust in PhIII

8 years ago

New PhIII data in hand, Pfizer, Astellas hustle ahead in bid to expand US market for Xtandi

8 years ago

Mustang ties the knot with Fred Hutch on next-gen CAR-T for lymphoma

8 years ago

AstraZeneca and Moderna take a big, early step forward in their quest to prove mRNA works in humans

8 years ago

Great data! Huge potential! (Too bad it failed the primary endpoint)

8 years ago

GSK lines up a shot at a blockbuster market as new CEO prepares to tackle Merck rival head on

8 years ago

Otonomy brings out the ax after a catastrophic PhIII failure

8 years ago

As rivals look to carve up its blockbuster revenue, Novartis’ Cosentyx registers remarkably consistent effect for psoriasis

8 years ago

Amicus scraps a top rare disease drug after it flunks a pivotal test — and shares spike

8 years ago

Alexion is reorganizing R&D, axing 600-plus jobs and moving HQ to Boston as execs prep deal spree

8 years ago

Sage’s quick flip into PhIII crashes as lead drug fails badly for rare type of seizures

8 years ago

Onxeo shares blitzed after PhIII liver cancer study flops

8 years ago

AbbVie stirs safety jitters after two patients die in ABT-494 study

8 years ago

Regeneron, Sanofi post good PhIII asthma data for Dupixent — but it’s losing its halo

8 years ago

#ESMO17 roundup: Idera shares spike on early TLR9 combo data; Erytech touts pancreatic cancer PhIIb data

8 years ago

#ESMO17: Roche extends losing streak with a setback for Zelboraf as Novartis combo surges ahead

8 years ago

J&J scraps a multibillion-dollar hepatitis C program after rivals divvy up the market

8 years ago

First page Previous page 291 292 293294295 296 297 Next page Last page